Ocrelizumab Linked to Improved Visual Outcomes in Relapsing MS

In pooled analysis from the phase 3 OPERA trials, low-contrast letter acuity showed improved visual outcomes in MS after treatment with ocrelizumab over interferon beta-1a.
Medscape Medical News

Full Story →